Início › Câncer de Rim (Carcinoma de Células Renais) › Minnesota › Rochester
Ensaios clínicos de Câncer de Rim (Carcinoma de Células Renais) em Rochester, MN
14 estudos para Câncer de Rim (Carcinoma de Células Renais) estão buscando participantes em locais em Rochester e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RecrutandoFase 1
- Mayo Clinic Rochester, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecrutandoFase 1
- Exelixis Clinical Site #68, Rochester
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecrutandoFase 2
- Mayo Clinic in Rochester, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecrutandoEstudo observacional
- Mayo Clinic Rochester, Rochester
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RecrutandoFase 2
- Mayo Clinic in Rochester, Rochester
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecrutandoFase 1/2
- Mayo Clinic Hospital, Methodist Campus, Research Pharmacy, Rochester
- Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecrutandoEstudo observacional
- Mayo Clinic (Rochester), Rochester
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RecrutandoFase 1
- Xencor Investigative Site, Rochester
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RecrutandoFase 1/2
- Mayo Clinic, Rochester
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RecrutandoFase 1
- Mayo Clinic Comprehensive Cancer Center, Rochester
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
RecrutandoFase 2
- Mayo Clinic in Rochester, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RecrutandoEstudo observacional
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecrutandoFase 1/2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecrutandoFase 1/2
- Mayo Clinic in Minnesota, Rochester
Ensaios de Câncer de Rim (Carcinoma de Células Renais) em outras cidades
- Houston, TX35 estudos
- New York City, NY27 estudos
- Dallas, TX23 estudos
- Nashville, TN23 estudos
- St. Louis, MO23 estudos
- Los Angeles, CA20 estudos
- Boston, MA16 estudos
- Baldwin Park, CA16 estudos
- Pittsburgh, PA15 estudos
- Philadelphia, PA15 estudos
- Queens, NY15 estudos
- Cleveland, OH14 estudos
Outros estudos em Rochester
- Câncer de Mama42 estudos
- Câncer de Pulmão de Não Pequenas Células37 estudos
- Câncer Metastático31 estudos
- Câncer (todos os tipos)30 estudos
- Câncer de Ovário29 estudos
- Câncer Colorretal29 estudos
- Mieloma Múltiplo24 estudos
- Insuficiência Cardíaca22 estudos
- Câncer de Próstata22 estudos
- Câncer de Pâncreas22 estudos
- Câncer Endometrial20 estudos
- Câncer de Pulmão20 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.